Cargando…

Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients

The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Arias-Murillo, Yazmin Rocio, Salinas-Nova, María Angélica, Caicedo, Tatiana, Galindo-Borda, Marisol, Meneses-Gil, Ximena, Montero, Camilo, Giron, Fernando, Pedraza, Nestor, Aroca, Gustavo, Ospina-Martinez, Martha Lucìa, Mercado-Reyes, Marcela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974356/
https://www.ncbi.nlm.nih.gov/pubmed/36997378
http://dx.doi.org/10.1016/j.transproceed.2023.02.034
_version_ 1784898709542141952
author Arias-Murillo, Yazmin Rocio
Salinas-Nova, María Angélica
Caicedo, Tatiana
Galindo-Borda, Marisol
Meneses-Gil, Ximena
Montero, Camilo
Giron, Fernando
Pedraza, Nestor
Aroca, Gustavo
Ospina-Martinez, Martha Lucìa
Mercado-Reyes, Marcela
author_facet Arias-Murillo, Yazmin Rocio
Salinas-Nova, María Angélica
Caicedo, Tatiana
Galindo-Borda, Marisol
Meneses-Gil, Ximena
Montero, Camilo
Giron, Fernando
Pedraza, Nestor
Aroca, Gustavo
Ospina-Martinez, Martha Lucìa
Mercado-Reyes, Marcela
author_sort Arias-Murillo, Yazmin Rocio
collection PubMed
description The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with CoronaVac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment.
format Online
Article
Text
id pubmed-9974356
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-99743562023-03-01 Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients Arias-Murillo, Yazmin Rocio Salinas-Nova, María Angélica Caicedo, Tatiana Galindo-Borda, Marisol Meneses-Gil, Ximena Montero, Camilo Giron, Fernando Pedraza, Nestor Aroca, Gustavo Ospina-Martinez, Martha Lucìa Mercado-Reyes, Marcela Transplant Proc Article The huge impact of SARS-CoV-2 infections on organ transplant recipients makes it necessary to optimize vaccine efficacy in this population. To effectively implement multiple strategies, it is crucial to understand the performance of each type of available vaccine. In our study, the antibody titer was measured, and the presence of antibodies against SARS-CoV-2 was evaluated after 90 days of immunization; furthermore, the differences between hybrid immunity, immunity by vaccination, and immunosuppressant type were identified. As a result, of the patients included in this study (n = 160), 53% showed antibodies against SARS-CoV-2 90 days after the first dose in patients who had completed the vaccination schedule. Antibody titers were higher in patients with hybrid immunity, and the proportion of nonresponsive patients was higher among those who received the immunosuppressant belatacept in their post-transplant regimen (P = .01). Only 15% of patients treated with this medicine seroconverted and patients vaccinated with CoronaVac and treated with belatacept showed no response. In conclusion, a reduced response to vaccines against SARS-CoV-2 was identified in the transplant population, and this response varied with the type of vaccine administered and the immunosuppressive treatment. Elsevier Inc. 2023-04 2023-03-01 /pmc/articles/PMC9974356/ /pubmed/36997378 http://dx.doi.org/10.1016/j.transproceed.2023.02.034 Text en © 2023 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Arias-Murillo, Yazmin Rocio
Salinas-Nova, María Angélica
Caicedo, Tatiana
Galindo-Borda, Marisol
Meneses-Gil, Ximena
Montero, Camilo
Giron, Fernando
Pedraza, Nestor
Aroca, Gustavo
Ospina-Martinez, Martha Lucìa
Mercado-Reyes, Marcela
Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients
title Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients
title_full Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients
title_fullStr Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients
title_full_unstemmed Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients
title_short Low Performance of Sinovac Vaccine Particularly With Belatacept Therapy in a Study With Different Types of COVID-19 Vaccines in Transplanted Patients
title_sort low performance of sinovac vaccine particularly with belatacept therapy in a study with different types of covid-19 vaccines in transplanted patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974356/
https://www.ncbi.nlm.nih.gov/pubmed/36997378
http://dx.doi.org/10.1016/j.transproceed.2023.02.034
work_keys_str_mv AT ariasmurilloyazminrocio lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT salinasnovamariaangelica lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT caicedotatiana lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT galindobordamarisol lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT menesesgilximena lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT monterocamilo lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT gironfernando lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT pedrazanestor lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT arocagustavo lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT ospinamartinezmarthalucia lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients
AT mercadoreyesmarcela lowperformanceofsinovacvaccineparticularlywithbelatacepttherapyinastudywithdifferenttypesofcovid19vaccinesintransplantedpatients